Trichome

Original file(1,079 × 1,510 pixels, file size: 293 KB, MIME type: image/jpeg)

Summary

This is a retouched picture, which means that it has been digitally altered from its original version.

Description
English: Two distinct TRPC5 mediated the cancer drug resistance. (a) TRPC5 overexpression activates the transcription factor NFATC3 Ca2+ signaling pathway, leading to p-gp overexpression. Moreover, the overexpressed p-gp expels chemotherapeutic drugs triggering chemoresistance. (b) Chemoresistant breast cancer cells overexpressing TRPC5 transfer channel units to chemo sensitive recipient cells via extracellular vesicles (EV), leading to the development of TRPC5-mediated chemoresistance in these cells.
Date
Source https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536409/
Author Mayar Soussi, Alice Hasselsweiller, and Dimitra Gkika

Licensing

w:en:Creative Commons
attribution
This file is licensed under the Creative Commons Attribution 4.0 International license.
You are free:
  • to share – to copy, distribute and transmit the work
  • to remix – to adapt the work
Under the following conditions:
  • attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Captions

TRPC5-mediated chemoresistance.

Items portrayed in this file

depicts

copyright status

copyrighted

copyright license

Creative Commons Attribution 4.0 International

inception

3 February 2024

File history

Click on a date/time to view the file as it appeared at that time.

Date/TimeThumbnailDimensionsUserComment
current03:45, 3 February 2024Thumbnail for version as of 03:45, 3 February 20241,079 × 1,510 (293 KB)PecMoUploaded a work by Mayar Soussi, Alice Hasselsweiller, and Dimitra Gkika from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536409/ with UploadWizard
The following pages on the English Wikipedia use this file (pages on other projects are not listed):

Metadata

Leave a Reply